Abbott Labs entering blood glucose monitoring market with $876 mil. MediSense buy.
This article was originally published in The Gray Sheet
Executive Summary
ABBOTT CATCHES RISING GLUCOSE MONITORING STAR MEDISENSE under an $876 mil. deal announced March 29. The definitive agreement, expected to be completed within the next five weeks, would give Abbott entry to the blood glucose monitor market with Waltham, Massachusetts-based MediSense's line of biosensor-based blood glucose systems for diabetes patient self-testing.
You may also be interested in...
J&J's $1.3 Bil. Inverness Buy Would End Royalty-Based Relationship
Johnson & Johnson's $1.3 bil. proposed acquisition of Inverness Medical Technology's diabetes care business builds on the firms' ongoing glucose meter and strip supply relationship begun in 1995.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.